A higher frequency of CD103+TCF1+ TRM cells (14.5%) was also observed in the total CD8+ T cell population in IRE+Combo-treated mouse TDLNs compared to the two control treatment groups (2.6% and 0.3%) (Figure 7C), which indicates that the 41BB-agonist can enhance CD8+ TRM cell responses and is consistent with a previous report that 41BB-agonist promoted expansion of tumor-infiltrating CTLs (51). This evidence concerns the gene CD8A and neoplasm.